ArticleJournal of thrombosis and haemostasis : JTH2026
Establishing the clinical utility of integrated quasistatic acoustic tweezing thromboelastometry for blood coagulation analysis.
Article in Journal of thrombosis and haemostasis : JTH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundRapid and accurate coagulation analysis is essential for managing critical care and surgical patients, patients with coagulation disorders, and patients with cardiovascular disease on anticoagulant therapy. Traditional assays often require large sample volumes, posing iatrogenic risks in vulnerable populations, including pediatric and elderly patients. Integrated quasistatic acoustic tweezing thromboelastometry (i-QATT) offers a comprehensive, noncontact assessment of coagulation using a 4- to 6-μL drop of blood that minimizes diagnostic errors associated with sample-container surface interactions.
objectivesThis study aims to assess the preliminary clinical utility of the i-QATT technique.
methodsUsing blood samples from healthy volunteers and liver transplant patients, as well as control plasmas, we established the reference ranges for i-QATT coagulation parameters and validated them across several abnormal conditions, including single-factor deficiencies, abnormal fibrinogen levels, unfractionated heparin anticoagulation, and coagulopathy.
resultsi-QATT identified coagulation abnormalities within 3 to 8 minutes. Its parameters showed strong correlations with gold-standard assay data, for example, activated partial thromboplastin time (r ≥ 0.81), international normalized ratio (r ≥ 0.74), thromboelastography (TEG) citrated kaolin channel parameters (R, K, α, and maximum width of TEG tracing [MA]; r ≥ 0.65), citrated rapid TEG (MA; r = 0.64), and TEG citrated functional fibrinogen (MA; r ≥ 0.64). i-QATT data demonstrated a near-linear response to unfractionated heparin concentrations spanning the prophylactic and therapeutic ranges (0-1 IU/mL; R
conclusionsThis study positions i-QATT as a highly sensitive, rapid, and ultra-low-volume alternative to conventional coagulation assays, with strong potential to transform point-of-care diagnostics across a wide range of clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.